Rick Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company employing approximately 25,000 people and marketing medicines in more than 170 countries. Prior to AbbVie's separation from Abbott, Mr. Gonzalez was a 30-year Abbott veteran. He served as Executive Vice President, Pharmaceutical Products Group, where he led the global pharmaceutical business, including commercial operations, research and development and manufacturing. He also served as President and Chief Operating Officer, prior to a brief retirement.
AbbVie is a research-based biopharmaceutical company.
On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The "new" Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based biopharmaceutical manufacturer.[2] The separation was effective January 1, 2013 and AbbVie was officially listed on the New York Stock Exchange (ABBV) on January 2, 2013.[3]
AbbVie is led by Richard A. Gonzalez, a 30-year Abbott veteran who served previously as Executive Vice President of Pharmaceuticals. He also served as Abbott’s President and Chief Operating Officer, prior to a brief retirement in 2007. AbbVie features adalimumab, marketed under the trade name Humira, a biologic treatment for autoimmune diseases that has exceeded $10 billion in global sales. AbbVie’s portfolio of medicines also includes AndroGel, Creon, Duodopa and Duopa, Kaletra, Lupron, Niaspan, Norvir, Sevoflurane, Synagis, Synthroid, TriCor and Trilipix, Viekira, and Zemplar.
